Francine Foss - Concepedia

Concepedia

Author

Francine Foss

Memorial Sloan Kettering Cancer Center

Also Known As

F Foss, F. Foss, Francine Foss, Francine Mary Foss

28

Publications

1.2K

Citations

10

H-Index

16

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Dana-Farber Cancer Institute Washington University in St. Louis Yale Cancer Center The University of Texas MD Anderson Cancer Center

FF

About

Francine Foss is an author at Memorial Sloan Kettering Cancer Center specializing in oncology, medicine, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	715
2	Pathology	2	2	639
3	Health Sciences	1	1	18
4	Immunology	1	1	18
5	Obstetrics	1	1	76

Francine Foss

×

10

Publications

1.2K

Citations

10

H-Index

	Year	Citations
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial Youn H. Kim, M. Bagot, Lauren Pinter‐Brown, The Lancet Oncology Cutaneous T-cell LymphomaLymphoid NeoplasiaMedicinePathologyMogamulizumab Versus Vorinostat	2018	621
Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study Michael S. Khodadoust, Alain H. Rook, Pierluigi Porcu, Journal of Clinical Oncology	2019	217
Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma Youn H. Kim, Francine Foss, Jasmine Zain, Blood	2012	130
A Phase II Trial of Daily Perillyl Alcohol in Patients with Advanced Ovarian Cancer: Eastern Cooperative Oncology Group Study E2E96 Howard H. Bailey, Donna E. Levy, Linda S. Harris, Gynecologic Oncology Phase Ii TrialDaily Perillyl AlcoholAdvanced Ovarian CancerMedicineGynecology	2002	76
T-Cell Lymphomas in South America and Europe Monica Bellei, Carlos Chiattone, Stefano Luminari, Revista Brasileira de Hematologia e Hemoterapia	2011	58
United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic John A. Zic, Weiyun Z. Ai, Oleg E. Akilov, Journal of the American Academy of Dermatology	2020	28
Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion Sarah Perreault, Molly Schiffer, Virginia Clinchy-Jarmoszko, American Journal of Health-System Pharmacy	2021	22
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study Dai Maruyama, Eric D. Jacobsen, Pierluigi Porcu, The Lancet Oncology	2024	21
Initial phase II results of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent systemic anaplastic large cell lymphoma (ALCL) Andres Forero, Sarah Bernstein, A. Gopal, Journal of Clinical Oncology ImmunologyPathologyImmunotherapeuticsAnti-cd30 Monoclonal AntibodyImmunotherapy	2005	18
A Phase I Open Label Dose Escalation Study To Evaluate MEDI-507 in Patients with CD2-Positive T-Cell Lymphoma/Leukemia. Deborah A. Casale, Nancy L. Bartlett, David D. Hurd, Blood	2006	13

Page 1